-
Selection process for future Olympic hosts set for reform
-
Serbian minister on trial over Trump-linked hotel plan
-
UK PM says Mandelson 'lied', regrets appointing him US envoy
-
Cochran-Siegle tops first Olympic downhill training
-
Gaza health officials say strikes kill 21 after Israel says shots wounded officer
-
Injured Vonn's Olympic bid is 'inspirational', ski stars say
-
Albania arrests 20 for toxic waste trafficking
-
US-Africa trade deal renewal only 'temporary breather'
-
Mir sets pace on Sepang day two, Yamaha absent
-
Xi, Putin hail 'stabilising' China-Russia alliance
-
GSK boosted by specialty drugs, end to Zantac fallout
-
UK's ex-prince leaves Windsor home amid Epstein storm: reports
-
Sky is the limit for Ireland fly-half Prendergast, says captain Doris
-
Feyi-Waboso reminds England great Robinson of himself
-
Starmer faces MPs as pressure grows over Mandelson scandal
-
HRW urges pushback against 'aggressive superpowers'
-
Russia demands Ukraine give in as UAE talks open
-
Gaza civil defence says 17 killed in strikes after Israel says shots wounded officer
-
France's Kante joins Fenerbahce after Erdogan 'support'
-
CK Hutchison launches arbitration over Panama Canal port ruling
-
Stocks mostly rise as traders ignore AI-fuelled sell-off on Wall St
-
Acclaimed Iraqi film explores Saddam Hussein's absurd birthday rituals
-
On rare earth supply, Trump for once seeks allies
-
Ukrainian chasing sumo greatness after meteoric rise
-
Draper to make long-awaited return in Davis Cup qualifier
-
Can Ilia Malinin fulfil his promise at the Winter Olympics?
-
CK Hutchison begins arbitration against Panama over annulled canal contract
-
UNESCO recognition inspires hope in Afghan artist's city
-
Ukraine, Russia, US negotiators gather in Abu Dhabi for war talks
-
WTO must 'reform or die': talks facilitator
-
Doctors hope UK archive can solve under-50s bowel cancer mystery
-
Stocks swing following latest AI-fuelled sell-off on Wall St
-
Demanding Dupont set to fire France in Ireland opener
-
Britain's ex-prince Andrew leaves Windsor home: BBC
-
Coach plots first South Africa World Cup win after Test triumph
-
Spin-heavy Pakistan hit form, but India boycott risks early T20 exit
-
Japan eyes Premier League parity by aligning calendar with Europe
-
Whack-a-mole: US academic fights to purge his AI deepfakes
-
Love in a time of war for journalist and activist in new documentary
-
'Unprecedented mass killing': NGOs battle to quantify Iran crackdown scale
-
Seahawks kid Cooper Kupp seeks new Super Bowl memories
-
Thousands of Venezuelans march to demand Maduro's release
-
AI, manipulated images falsely link some US politicians with Epstein
-
Move on, says Trump as Epstein files trigger probe into British politician
-
Axon Neuroscience's Immunotherapy Selected for a Landmark Combination-Therapy Alzheimer’s Clinical Trial in US, Supported by a USD 151 Million Grant
-
CHAR Technologies Licenses High-Temperature Pyrolysis Technology to GazoTech SAS for Entry Into European Markets
-
Arteta backs Arsenal to build on 'magical' place in League Cup final
-
Evil Empire to underdogs: Patriots eye 7th Super Bowl
-
UBS grilled on Capitol Hill over Nazi-era probe
-
Guardiola 'hurt' by suffering caused in global conflicts
Chinese medical portal censored after doubting herbal 'Covid remedy'
A popular Chinese medical information site has been censored by authorities for "violation of relevant laws and regulations", months after its criticism of a government-backed herbal Covid-19 treatment sent shares in a pharmaceutical giant tumbling.
DXY, which counts tech giant Tencent among its investors and runs a host of health-related services, previously questioned the value of Lianhua Qingwen, a herbal remedy marketed for fever and sore throats, as a Covid-19 treatment.
China approved the concoction -- made up of ingredients like honeysuckle and apricot seeds -- as a Covid-19 treatment in 2020, and it was distributed to Shanghai residents during the city's outbreak this year.
DXY's article was part of a wave of reports that caused shares in Lianhua Qingwen's producer -- one of China's largest traditional medicine companies -- to plunge.
The website has now been banned from posting on at least five of its Weibo social media accounts, with a notice at the top of its official page saying that due to "violation of relevant laws and regulations, this user is currently prohibited from posting".
DXY's official WeChat accounts, which typically publish multiple articles a day on medical topics, have not been updated since Monday.
The Weibo notice did not specify which regulations had been violated by DXY, which did not immediately respond to AFP's request for comment.
The Chinese government has increasingly promoted traditional medicine at home and abroad in recent years, often with nationalistic undertones.
DXY's coverage prompted criticism that it was targeting traditional Chinese medicine (TCM) in order to promote Western pharmaceuticals.
The United States and other countries have warned there is no evidence Lianhua Qingwen works to prevent or cure Covid-19, even as it has increasingly been promoted by government authorities in China and Hong Kong.
The US Food and Drug Administration has said it has not approved Lianhua Qingwen and that coronavirus-related claims about it were "not supported by competent and reliable scientific evidence".
Beijing issued its first white paper on TCM in 2016, laying out plans to build medicine centres and dispatch practitioners to developing countries in Africa and Southeast Asia.
President Xi Jinping has described TCM as a "treasure of Chinese civilisation" and has said that it should be given as much weight as other treatments.
Beijing's National Health Commission has also dispatched TCM practitioners as part of its medical reinforcement teams sent to fight Covid-19 outbreaks across the country.
G.Teles--PC